Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ATYR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsaTyr Pharma redesigns Phase 3 trial for efzofitimod after FDA feedback, targets narrower patient group
Filed May 11, 2026 · Period ending May 11, 2026 · ~1 min read
Key Changes
-
high
aTyr will launch new Phase 3 trial focusing on pulmonary sarcoidosis patients with restrictive lung disease (FVC ≤80%), using lung capacity as primary endpoint instead of previous design. IND submission planned for June 2026.
Item 7.01 verify on EDGAR → -
high
Dosing frequency increased to every 3 weeks (from every 4 weeks) based on FDA discussions about benefit-risk profile. Trial will include enhanced safety monitoring and data safety committee oversight.
Item 7.01 verify on EDGAR → -
high
New global trial will enroll approximately 372 patients over 54 weeks. Design based on subgroup showing 124 ml FVC improvement in 44 restrictive disease patients from prior EFZO-FIT study.
Item 7.01 verify on EDGAR → -
medium
Company reports preliminary Q1 2026 cash position of approximately $68.3 million as of March 31, 2026 (unaudited management estimate).
Item 7.01 verify on EDGAR →
Summary
aTyr Pharma is pivoting its lead drug development program after FDA feedback on its previous Phase 3 trial. The company will redesign its efzofitimod study for pulmonary sarcoidosis, narrowing the patient population to those with restrictive lung disease and changing the primary endpoint to forced vital capacity (FVC), a direct measure of lung function.
The FDA guidance suggests regulators want clearer evidence of clinical benefit in a more defined patient group. The company is also intensifying the dosing schedule and adding safety monitoring protocols. This represents a material strategic shift that will likely extend the timeline to potential approval.
While the subgroup data showing 124 ml FVC improvement provides scientific rationale, investors should note this was only 44 patients from the prior study. The company plans to submit the new trial design to FDA in June 2026, which will be the next key milestone. With $68.3 million in cash reported as of March 31, investors should watch for updates on cash runway relative to the new trial timeline and potential need for additional financing.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Item 2.02 — Results of Operations and Financial Condition filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
As of March 31, 2026, aTyr Pharma, Inc. (the Company) had approximately $68.3 million of cash, cash equivalents, restricted cash and available-for-sale investments.
The company disclosed its preliminary cash and investment position as of the end of Q1 2026, totaling approximately $68.3 million. This is unaudited and represents management's estimate, with actual results potentially differing materially.
Event · Item 7.01 — Regulation FD Disclosure
aTYR released a corporate presentation on regulatory and clinical updates for efzofitimod in pulmonary sarcoidosis.
Added in current filing · verify on EDGAR →
On May 11, 2026, the Company made available a corporate presentation regarding a regulatory and clinical update with respect to the Company's continued development of efzofitimod in pulmonary sarcoidosis
The company disclosed a corporate presentation providing regulatory and clinical updates on efzofitimod, its drug candidate for treating pulmonary sarcoidosis. This is a Regulation FD disclosure, meaning the information is being made publicly available to all investors simultaneously. The presentation is attached as an exhibit but the 8-K itself does not detail the specific updates contained within.
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Based on feedback from the FDA, the Company plans to continue the development of efzofitimod in pulmonary sarcoidosis in a new Phase 3 study in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease utilizing forced vital capacity (FVC) as the primary endpoint of the study and the King’s Sarcoidosis Questionnaire (KSQ)-Lung score as the key secondary endpoint.
Following FDA Type C meeting feedback on the Phase 3 EFZO-FIT study results, aTYR is redesigning its Phase 3 program. The new trial will focus on a narrower patient population (those with restrictive lung disease, defined as FVC ≤80%) and use FVC as the primary endpoint instead of the previous design. This represents a strategic pivot based on regulatory guidance that FVC and KSQ-Lung are direct measures of patient function and symptoms.
Added in current filing · verify on EDGAR →
As part of the Company’s discussion with the FDA regarding the benefit risk profile for efzofitimod, the Company plans to increase the frequency of dosing of 5.0 mg/kg efzofitimod or placebo from once every four weeks in past trials to once every three weeks in this next trial.
The dosing regimen is being intensified from every 4 weeks to every 3 weeks (17 total doses over 54 weeks). The FDA acknowledged this as reasonable from a clinical pharmacology perspective, subject to adequate safety monitoring. The company will implement additional risk mitigation strategies including enhanced surveillance for anti-synthetase syndrome and a data safety monitoring committee.
Added in current filing · verify on EDGAR →
The Phase 3 trial is expected to be a global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efzofitimod in patients with moderate to severe pulmonary sarcoidosis. The 54-week study will consist of two parallel cohorts randomized equally to either 5.0 mg/kg efzofitimod or placebo dosed intravenously once every 3 weeks for a total of 17 doses. The study is intended to enroll up to approximately 372 patients with symptomatic pulmonary sarcoidosis with restrictive lung disease who are receiving a stable dose of ≤ 5.0 mg daily oral corticosteroid and/or a background immunosuppressant.
The new Phase 3 study will enroll approximately 372 patients globally in a 54-week trial. Patients must have restrictive lung disease and be on stable background therapy. The company plans to submit an IND application for this study in June 2026, representing a near-term regulatory milestone.
Added in current filing · verify on EDGAR →
The Company determined the patient population for the study, those with restrictive lung disease, based on data from the EFZO-FITTM study which included 44 patients with restrictive lung disease (defined as FVC percent predicted ≤ 80%) and showed a difference of 124 ml in change from baseline in FVC between restrictive patients treated with 5.0 mg/kg efzofitimod and placebo.
The rationale for narrowing to restrictive lung disease patients comes from a subgroup analysis of the prior EFZO-FIT study. In 44 patients with FVC ≤80%, efzofitimod showed a 124 ml improvement in FVC versus placebo, suggesting this population may be more responsive to treatment.
Event · Item 9.01 — Financial Statements and Exhibits
aTyr Pharma filed an 8-K to disclose corporate presentation materials dated May 11, 2026.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
99.1
Corporate Presentation Materials of aTyr Pharma, Inc. dated May 11, 2026
The company filed corporate presentation materials dated May 11, 2026 as Exhibit 99.1. This is a routine disclosure of investor or corporate presentation slides, typically used for conferences, investor meetings, or public communications about the company's business and strategy.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify